Literature DB >> 20533031

The role of (18)F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours.

Bernadette G Dijkman1, Olga C J Schuurbiers, Dennis Vriens, Monika Looijen-Salamon, Johan Bussink, Johanna N H Timmer-Bonte, Miranda M Snoeren, Wim J G Oyen, Henricus F M van der Heijden, Lioe-Fee de Geus-Oei.   

Abstract

PURPOSE: In lung cancer patients with multiple lesions, the differentiation between metastases and second primary tumours has significant therapeutic and prognostic implications. The aim of this retrospective study was to investigate the potential of (18)F-FDG PET to discriminate metastatic disease from second primary lung tumours.
METHODS: Of 1,396 patients evaluated by the thoracic oncology group between January 2004 and April 2009 at the Radboud University Nijmegen Medical Centre, patients with a synchronous second primary lung cancer were selected. Patients with metastatic disease involving the lungs served as the control group. Maximum standardized uptake values (SUVs) measured with (18)F-FDG PET were determined for two tumours in each patient. The relative difference between the SUVs of these tumours (∆SUV) was determined and compared between the second primary group and metastatic disease group. Receiver-operating characteristic (ROC) curve analysis was performed to determine the sensitivity and specificity of the ∆SUV for an optimal cut-off value.
RESULTS: A total of 37 patients (21 metastatic disease, 16 second primary cancer) were included for analysis. The ∆SUV was significantly higher in patients with second primary cancer than in those with metastatic disease (58 vs 28%, respectively, p < 0.001). The area under the ROC curve was 0.81 and the odds ratio for the optimal cut-off was 18.4.
CONCLUSION: SUVs from (18)F-FDG PET images can be helpful in differentiating metastatic disease from second primary tumours in patients with synchronous pulmonary lesions. Further studies are warranted to confirm the consistency of these results.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20533031      PMCID: PMC2948164          DOI: 10.1007/s00259-010-1505-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  41 in total

1.  Six synchronous primary neoplasms detected by FDG-PET/CT.

Authors:  Miraude Adriaensen; Laura Schijf; Marie de Haas; Julia Huijbregts; Henk-Jan Baarslag; Gerald Staaks; John de Klerk
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-06       Impact factor: 9.236

2.  The origins of multiple squamous cell carcinomas in the aerodigestive tract.

Authors:  M G van Oijen; F G Leppers Vd Straat; M G Tilanus; P J Slootweg
Journal:  Cancer       Date:  2000-02-15       Impact factor: 6.860

3.  The prognostic significance of a previous malignancy in operable non-small cell lung cancer.

Authors:  M J Koppe; F A Zoetmulder; N van Zandwijk; A A Hart; P Baas; E J Rutgers
Journal:  Lung Cancer       Date:  2001-04       Impact factor: 5.705

Review 4.  Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review.

Authors:  Lioe-Fee de Geus-Oei; Henricus F M van der Heijden; Frans H M Corstens; Wim J G Oyen
Journal:  Cancer       Date:  2007-10-15       Impact factor: 6.860

5.  Multiple independent primary cancers do not adversely affect survival of the lung cancer patient.

Authors:  Rafael Aguiló; Francesc Macià; Miquel Porta; Montserrat Casamitjana; Joan Minguella; Ana Maria Novoa
Journal:  Eur J Cardiothorac Surg       Date:  2008-09-27       Impact factor: 4.191

6.  Standardized uptake values of FDG: body surface area correction is preferable to body weight correction.

Authors:  C K Kim; N C Gupta; B Chandramouli; A Alavi
Journal:  J Nucl Med       Date:  1994-01       Impact factor: 10.057

7.  Epidemiology of multiple primary cancers.

Authors:  Isabelle Soerjomataram; Jan Willem Coebergh
Journal:  Methods Mol Biol       Date:  2009

8.  Esophageal and laryngeal cancer incidentally found on [18F]fluorodeoxyglucose positron emission tomography/computed tomography during the staging workup for lung cancer.

Authors:  Se Yong Jeon; Se Han Ahn; Cheol Hyeon Kim; Sang Moo Lim; Jae Soo Koh; Jae Cheol Lee
Journal:  Clin Lung Cancer       Date:  2008-07       Impact factor: 4.785

9.  Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma.

Authors:  P P Leong; B Rezai; W M Koch; A Reed; D Eisele; D J Lee; D Sidransky; J Jen; W H Westra
Journal:  J Natl Cancer Inst       Date:  1998-07-01       Impact factor: 13.506

10.  Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer.

Authors:  H-J Jeong; J-J Min; J M Park; J-K Chung; B T Kim; J M Jeong; D S Lee; M C Lee; S K Han; Y S Shim
Journal:  Nucl Med Commun       Date:  2002-09       Impact factor: 1.690

View more
  23 in total

1.  A novel molecular pathway for Snail-dependent, SPARC-mediated invasion in non-small cell lung cancer pathogenesis.

Authors:  Jeanette L Grant; Michael C Fishbein; Long-Sheng Hong; Kostyantyn Krysan; John D Minna; Jerry W Shay; Tonya C Walser; Steven M Dubinett
Journal:  Cancer Prev Res (Phila)       Date:  2013-11-19

2.  Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients.

Authors:  Charline Lasnon; Cédric Desmonts; Elske Quak; Radj Gervais; Pascal Do; Catherine Dubos-Arvis; Nicolas Aide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-06       Impact factor: 9.236

3.  Synchronous non small cell lung cancer nodules treated with stereotactic body radiation therapy (SBRT).

Authors:  Aryavarta M S Kumar; Neil M Woody; Toufik Djemil; Gregory M M Videtic; Kevin L Stephans
Journal:  J Radiosurg SBRT       Date:  2014

4.  Are there imaging characteristics that can distinguish separate primary lung carcinomas from intrapulmonary metastases using next-generation sequencing as a gold standard?

Authors:  Jose Arimateia Batista Araujo-Filho; Jason Chang; Maria Mayoral; Andrew J Plodkowski; Rocio Perez-Johnston; Stephanie Lobaugh; Junting Zheng; Valerie W Rusch; Natasha Rekhtman; Michelle S Ginsberg
Journal:  Lung Cancer       Date:  2021-01-25       Impact factor: 5.705

5.  [Research Progress in Distinguishing Methods of Simultaneous Multiple Primary Lung Cancer and Intrapulmonary Metastasis].

Authors:  Jifan Wang; Te Zhang; Hanlin Ding; Gaochao Dong; Lin Xu; Feng Jiang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-05-20

6.  CT and PET-CT of a dog with multiple pulmonary adenocarcinoma.

Authors:  Jisun Kim; Seong Young Kwon; Rohani Cena; Seungjo Park; Juyeon Oh; Heejin Oui; Kyoung-Oh Cho; Jung-Joon Min; Jihye Choi
Journal:  J Vet Med Sci       Date:  2013-12-31       Impact factor: 1.267

7.  Impact of point spread function modelling and time of flight on FDG uptake measurements in lung lesions using alternative filtering strategies.

Authors:  Ian S Armstrong; Matthew D Kelly; Heather A Williams; Julian C Matthews
Journal:  EJNMMI Phys       Date:  2014-11-30

8.  Imaging in thoracic oncology: case studies from Multidisciplinary Thoracic Tumor Board: (part 2 of 2 part series).

Authors:  Leslie E Quint; Rishindra M Reddy; Jules Lin; Douglas A Arenberg; Corey Speers; James A Hayman; Fengming P Kong; Mark B Orringer; Gregory P Kalemkerian
Journal:  Cancer Imaging       Date:  2013-12-06       Impact factor: 3.909

9.  Unusual synchronous lung tumors: mucoepidermoid carcinoma and mucinous adenocarcinoma.

Authors:  Ana M Ponea; Creticus P Marak; Ying Sun; Achuta Kumar Guddati; Amit S Tibb
Journal:  Case Rep Oncol Med       Date:  2014-02-18

10.  The more you look, the more you find: challenging results on FDG-PET CT in a patient with neurofibromatosis type I.

Authors:  Patrick Schöffski; Christophe M Deroose; Olivier Gheysens; Nele Lips; Koen Slabbaert; Ben Vancleynenbreugel; Philippe Moerman; Willy E Peetermans
Journal:  BMC Med Imaging       Date:  2014-05-29       Impact factor: 1.930

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.